Upfront Briefing
Vera finally got the FDA to sign the slip: atacicept — now Trutakna — cleared accelerated approval in IgA nephropathy, flipping a clinical-stage story into a launch story and dropping it straight into a cage match with Novartis and Otsuka.
The deal machine didn't sleep either: AstraZeneca paid Sino up to $2.1B to challenge Merck's Ohtuvayre in COPD, Kailera's oral GLP-1 cleared Phase 3 (with a tolerability asterisk), and — ICYMI — BioCentury tallied ~$13B of rare-disease takeouts last week, Vertex's $10B Crinetics grab leading. China's fingerprints are all over today's tape.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,503.9 |
(0.4%) |
9.4% |
| Nasdaq 100 |
29,173.0 |
(1.8%) |
15.7% |
| Russell 2000 |
2,982.5 |
(0.9%) |
18.9% |
| Healthcare (XLV) |
164.4 |
1.5% |
5.7% |
| Biotech (XBI) |
163.9 |
1.9% |
34.9% |
| Nasdaq Biotech (NBI) |
6,856.7 |
1.7% |
20.2% |
| Clinical Trials (BBC) |
54.2 |
2.7% |
44.0% |
|
- Biotech ran counter to the tape — XBI +1.9%, NBI +1.7% and BBC +2.7% while the Nasdaq 100 fell 1.8% — powered by Vera's FDA accelerated approval for atacicept (Trutakna) in IgA nephropathy and the rolling rare-disease M&A bid behind Vertex's $10B Crinetics takeout.
- The broad tape sank on a chip rout: a semiconductor gauge fell ~4.5% after Samsung's record Q2 profit missed the loftiest estimates and Reuters reported DeepSeek is building its own inference chip, while crude jumped >5% (Brent above $76) after the U.S. revoked Iran's oil-sale waiver amid Strait of Hormuz attacks, lifting yields.
- Market data: U.S. cash close Tuesday, 7 July 2026.
The Big 3
|
1
|
Vera lands FDA accelerated approval for atacicept in IgAN
|
- The FDA granted Vera's atacicept (Trutakna) accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, on a 46% reduction from baseline — 42% vs placebo (p<0.0001) — in the Phase 3 ORIGIN 3 interim.
- Why it matters: Trutakna is the first dual BAFF/APRIL inhibitor cleared in IgAN, and Vera (Nasdaq: VERA, ~$3B cap) flips from clinical risk to launch execution with a clean, once-weekly autoinjector label. It lands in a suddenly crowded field — head-to-head with Novartis' Fabhalta and Otsuka's Voyxact, with Vertex a looming entrant via Alpine's povetacicept — so share of a large, chronic proteinuria market is the swing factor. The catch: this is accelerated approval on a proteinuria surrogate, not kidney-function benefit; continued approval hinges on confirmatory eGFR data from ORIGIN 3 due later this quarter.
- Source: BioSpace
- More: FDA
|
|
2
|
Kailera's oral GLP-1 posts 11% weight loss in Chinese Phase 3
|
- Hengrui's once-daily oral GLP-1 HRS-7535 (Kailera's KAI-7535) hit its primary endpoints in Phase 3 obesity and Type 2 diabetes trials — up to 10.9% mean weight loss at Week 44 vs 2.5% on placebo (9.8% on the treatment-policy estimand), plus HbA1c cuts up to 1.68% in T2D.
- Why it matters: This is the first Phase 3 read on Kailera's ex-Greater China oral GLP-1, and it drops straight into the oral-obesity race against Lilly's orforglipron (~11.1% at Week 72) and Novo's oral semaglutide (~13.6% at Week 64) — efficacy in the same band, so the fight is tolerability. That's the catch: nausea ran at 70% and vomiting at ~69% (vs 4.5% placebo), well above either rival's oral program, which could cap real-world dosing and share. Kailera (public since its $625M April IPO) holds only ex-China rights, and the data are China-only — global filings will need bridging, with the usual COINS-era overhang on China-originated packages.
- Source: Fierce Biotech
- More: GlobeNewswire
|
| 3 | AstraZeneca pays Sino $2.1B for a COPD shot at Merck's Ohtuvayre |
- AstraZeneca licensed ex-China rights to Sino Biopharmaceutical's PDE3/4 inhibitor TQC3721 for $200M upfront and up to $1.9B in milestones ($2.1B total), plus rights to certain future programs; the nebulized COPD candidate is in Phase 3 in China.
- Why it matters: This is AstraZeneca crashing the PDE3/4 party Merck just paid $10B (Verona) to own — TQC3721 posted a +147 mL peak-FEV1 bump at Week 4 in Phase 2 vs Ohtuvayre's +124 mL, though that's cross-trial, not head-to-head. Ohtuvayre did just $131M in Q1 against "multibillion" peak talk, so the market AZ is buying into is early and contested; AZ can lean on its Breztri/Symbicort COPD franchise ($1.2B Q1) and a stacked bench (tozorakimab, AZD6793). The risk: another China-originated package (Sino's Chia Tai Tianqing unit), so it carries the COINS Act overhang now drawing House Select Committee scrutiny, and China-only data will need global bridging.
- Source: Fierce Biotech
|
Everything Else that broke
- In another Makary-era reversal, the FDA told Saol it can resubmit its ultra-rare-disease NDA without a new trial, trimming the time and cost to refile. — BioCentury
- Whitehawk struck a global collaboration with China's Biocytogen to develop up to five bispecific ADCs off the RenLite platform, on undisclosed upfront and milestones. — Fierce Biotech
- MeiraGTx secured up to $400M from Oberland Capital — $125M upfront for low-single-digit royalties plus a $10M equity stake — to push its XLRP and dry-mouth gene therapies toward launch. — Fierce Biotech
- The House Select Committee on China pressed Pfizer, Merck, BMS and AbbVie over trials run at Xinjiang and military-linked sites, sharpening the COINS Act-era overhang on China-sourced R&D. — Fierce Biotech
- Tampa General sued Eli Lilly over 340B discount restrictions tied to new claims-data requirements. — Endpoints
- Vanda won rare pediatric disease designation for VCA-894A, its ASO for Charcot-Marie-Tooth disease type 2S. — PR
- TaiMed got the final TFDA notice for Trogarzo ahead of commercial launch in Taiwan with Orient EuroPharma. — PR
- Takeda's orexin program got a fresh strategic review as oveporexton keeps narcolepsy investors interested. — BioCentury
- Wave set a July 14 Singapore court hearing for its redomiciliation scheme to the United States. — PR
- ARS Pharmaceuticals kicked off a CEO succession, with co-founder Richard Lowenthal stepping back after more than a decade. — PR
- Langar's Global HealthTech ETF will shift its primary listing from NYSE Arca to Cboe BZX. — PR
- LIFE reported another own-share acquisition update, keeping an uncommon buyback program in view. — PR
- Addex highlighted published research linking mGlu7 modulation to sleep and wakefulness. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- ICYMI: Vertex / Crinetics — $10B acquisition; rare endocrinology (paltusotine, atumelnant) as a new commercial pillar. — Bloomberg
- AstraZeneca / Sino Biopharmaceutical — ex-China license to PDE3/4 inhibitor TQC3721 (COPD); $200M upfront, up to $1.9B milestones. — Fierce Biotech
- Whitehawk / Biocytogen — global collaboration to develop up to five bispecific ADCs (RenLite platform); undisclosed upfront + milestones. — Fierce Biotech
- Boehringer Ingelheim / Prime Vector Technologies — exclusive license to the ORFV viral-vector platform for cancer vaccines; undisclosed terms. — Fierce Biotech
- Vivani signed a non-exclusive Novo Nordisk evaluation agreement for NPM-139, its ultra-long-acting semaglutide implant. — PR
VC / Private Financings
- BioSpace said the five largest VC rounds of H1 2026 still sit against years-low early-stage funding. — BioSpace
IPOs / Follow-Ons
- No notable IPOs / follow-ons in the last 24 hours. — PR
Academic Corner - A phase 1 trial found bispecific antibody 10E8.4/iMab was safe, well tolerated, and showed antiviral activity in people with or without HIV-1. — Nature Medicine
|
